The AsthmaCo. June 2013

$8.9B Problem in Asthma SALBUTAMOL (a.k.a. Albuterol) is the ONLY short-acting bronchodilator – several “me toos” - all act via same B-adrenergic pathway $1.6B sales, 4 th most prescribed, 15 th highest selling GENERIC worldwide When Salbutamol doesn’t work… 3.9M Emergency Department visits / yr TREATED WITH SALBUTAMOL AGAIN! – no other options exist $2.1B: 85% sent home after 3 hrs $6.8B: 15% take up 1.8M hospital bed-days >10,000 deaths worldwide WHAT IS NEEDED: NEW Short-Acting Bronchodilator, with NEW mechanism of action

Canadian Asthma Research Leads to New Drug Discovery NEW mechanism of action Mucous plugsDrugs can’t get to where they are needed

New Treatment: S-1226 TM Perflubron mixed with CO 2 -enriched air Short-Acting Bronchodilator Constituents are well described, safe Constituents have previously been approved by FDA, EMA, etc… NEW mechanism of action Superior to Salbutamol! Perflubron CO 2 Circulaire II S-1226 TM

Faster Than Salbutamol 0 second treatment 2 seconds treatment 3 seconds treatment 1 second treatment 4 seconds treatment Pre-MChPost-MCh Tissue dye

More Potent and Longer-Lasting than Salbutamol

Patented in Major Markets Issued in US and Europe Pending in other jurisdictions Claims: Composition of matter and method to treat Monotherapy and in combination

Markets Emergency Department: “preceding salbutamol for acute asthma exacerbation” Estimated at $190M Peak Sales Less than 10% COGS – approximately $13/unit Personal rescue device Estimated at up to $2.9B Peak Sales Combination drug Estimated at $2B - $4B Peak Sales

Partners Proprietary nebulizer Exclusive Perflubron supply (marketed as Perflubronc® by Origen Biomedical) Phase I Clinical Trial Phase IIa Clinical Trial Development Partner Candidates

Team Management Experienced in the business, and top scientists Board of Directors Extremely successful at growing and selling respiratory medicine companies Advisors Highly networked, experienced

Nonclinical Research Drug Screening ✓ Compare vs Salbutamol ✓ Find Optimal Dose ✓ Manufacturing Build Prototype ✓ Secure Suppliers ✓ Minimize COGS ✓ Large-Scale Clinical Development Receive NOL ✓ Phase I Phase IIa Phase IIb Phase III Marketing Secure Marketing Partner Marketing Clearance Launch US VCs & Partn ers US VCs & Partn ers Corporate Development EXIT - Acquisition Corp Off. in US Corp Off. in US - July Award PrototypeProof of Concept Market Test Exit

US Expansion Interest expressed by: Boston Harbor Angels, Lead: Bill McPhee Mass Medical Angels, Lead: Frank Bobe Launchpad, Lead: Eduardo Pontoriero Office in Cambridge, MA Canadian Technology Accelerator Selected in a highly competitive application process Cambridge Innovation Center Office Other MIT VMS, Lead: Jerome Smith Keiretsu Forum, Lead: Thealzel Lee

S-1226™ is De-Risked Animal Studies Pre-clinicalPhase IPhase IIa Phase IIbPhase IIIApproval Regulatory Approval Statistically Significant Data Controlled Human Efficacy Toxicity Proof of Concept & Animal Studies Risk Manufacturing Real World Efficacy Manufacturing - 510(k) Efficacy – sheep, humans Toxicity – past studies S-1226™

Future Partnerships We are seeking additional strategic partnerships to help fund, develop, and commercialize S-1226™